First-Line Combo Immunotherapy Improves PFS in High TMB Non-Small Cell Lung Cancer
February 5th 2018The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival (PFS) compared with chemotherapy in treatment-naïve patients with high tumor mutation burden (TMB) non–small cell lung cancer (NSCLC).
Read More
Opinion: A Reaction to DEA's Efforts to Target Pharmacies with 'Unusual' Opioid Prescription Rates
February 5th 2018Although it is unclear what constitutes “unusual or disproportionate,” such phrases are particularly disturbing when we realize that the regulation of medical practice is a traditional state function, not a federal one.
Read More
Combo Inhibitor Antibiotic Approved to Treat HABP/VABP
February 3rd 2018The US Food and Drug Administration has approved Allergan's supplemental New Drug Application to expand the approved use of their cephalosporin / beta-lactamase inhibitor combo antibiotic, AVYCAZ (ceftazidime and avibactam), to include the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Gram-negative microorganisms: Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenzae in patients 18 years of age or older.
Read More
Flu Hospitalizations Reach Record High as Activity Escalates
February 3rd 2018This year’s flu season is on track to exceed previous seasons of high severity in hospitalization rates as influenza activity and related deaths continue to climb across the United States, according to a CDC media briefing held today.
Read More